• Home
  • The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.

The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.

Author List
Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR, Griffith OL, Korkola JE, Qu K, Lawson DA, Xue Q, Sternlicht MD, Dijkgraaf GJ, Yaswen P, Rugo HS, Sweeney CA, Collins CC, Gray JW, Chang HY, Werb Z
Publication
Cancer discovery
Publication ID (Profile URL)
https://researcherprofiles.org/profile/1162953
Publication Year
2012
PubMed ID
22728437
Publication Title
Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR, Griffith OL, Korkola JE, Qu K, Lawson DA, Xue Q, Sternlicht MD, Dijkgraaf GJ, Yaswen P, Rugo HS, Sweeney CA, Collins CC, Gray JW, Chang HY, Werb Z. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov. 2012 Jul; 2(7):638-51.